Join and get a FREE U-M rug or charcuterie board

Tofacitinib Shows Promise in Scleroderma Patients, Researchers are Optimistic for Next Phase of study.

October 6, 2022


Read time:

5-15 mins
Muscle Fiber Microscopic Scleroderma Fibrosis
Presented by Health Lab

Systemic sclerosis, or scleroderma that impacts the skin and internal organs, is one of the rarest autoimmune diseases, affecting over 80,000 people in the United States. Researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases. Dinesh Khanna M.B.B.S., M.Sc., director of the Michigan Medicine Scleroderma Program, discusses any clinical benefits of tofacitinib to patients and how the drug can work in the future.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.